(NASDAQ: IONS) Ionis Pharmaceuticals's forecast annual revenue growth rate of 6.17% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 78.34%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.8%.
Ionis Pharmaceuticals's revenue in 2025 is $944,051,000.On average, 9 Wall Street analysts forecast IONS's revenue for 2025 to be $133,162,445,921, with the lowest IONS revenue forecast at $117,471,335,773, and the highest IONS revenue forecast at $151,769,140,429. On average, 10 Wall Street analysts forecast IONS's revenue for 2026 to be $130,700,488,998, with the lowest IONS revenue forecast at $98,953,262,788, and the highest IONS revenue forecast at $153,493,753,527.
In 2027, IONS is forecast to generate $180,083,079,566 in revenue, with the lowest revenue forecast at $64,394,056,516 and the highest revenue forecast at $218,110,957,764.